Paper Details

  1. Home
  2. Paper Details

[Pharmacovigilance update].

Author: LivioF

English AbstractA summary of a research paper/publication written in English for a wider audience.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
ReviewAn article that critically examines existing research on a particular topic and summarizes the current state of knowledge in the field.

Overview

This review summarizes important pharmacovigilance updates from 2012. Key updates include increased bleeding risk in elderly patients with renal failure taking dabigatran, harmful effects of dual renin-angiotensin-aldosterone system blockade, a low risk of acute pancreatitis with incretin use, rhabdomyolysis risk with fusidic acid and statin co-administration, complex but manageable interactions between boceprevir/telaprevir and antiretroviral therapies, reduced maximum recommended doses for citalopram and ondansetron, increased blood pressure and heart rate with atomoxetine use, common elevated liver enzymes with agomelatine, and stronger safety recommendations for fingolimod use in patients with heart conditions.
Paper Details　
Original Abstract of the Article :
Main pharmacovigilance updates in 2012 are reviewed here. Dabigatran: elderly patients with renal failure are at higher risk of bleeding. Dual renin-angiotensin-aldosterone system blockade comprising aliskiren is harmful. Incretins: low risk of acute pancreatitis. Interaction between fusidic acid an...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://pubmed.ncbi.nlm.nih.gov/23367709

データ提供：米国国立医学図書館（NLM）

Pharmacovigilance: Ensuring Drug Safety in a Dynamic World

Pharmacovigilance, the science of monitoring drug safety, is crucial for ensuring the well-being of patients. This review provides an overview of key pharmacovigilance updates from 2012, highlighting emerging safety concerns and evolving guidelines. The review covers a range of drugs, including dabigatran, aliskiren, incretins, fusidic acid, statins, citalopram, ondansetron, atomoxetine, agomelatine, and fingolimod. It discusses the importance of ongoing monitoring and research to identify potential drug-related risks and develop strategies for mitigating these risks. It's like a watchful camel guarding a caravan of drugs, ensuring their safe passage through the desert of healthcare.

A Constant Vigil: Protecting Patients from Drug-Related Risks

This review emphasizes the importance of continuous vigilance in drug safety monitoring. The ever-evolving nature of medicine requires a constant adaptation and update of safety guidelines. It's like a camel trekking through a changing desert landscape, needing to adjust its course to avoid potential hazards. This ongoing process is essential for protecting patients and ensuring the safety of medications.

Informed Decision-Making: Empowering Patients and Healthcare Providers

By staying informed about drug safety updates, patients and healthcare providers can make more informed decisions about medication use. This review serves as a valuable resource, providing insights into potential drug risks and strategies for minimizing these risks. It's like providing a compass and a map to guide us through the desert of drug information, allowing us to make safe and effective choices.

Dr.Camel's Conclusion

Like a camel traversing a vast and unpredictable desert, drug safety monitoring requires careful observation and adaptability. This review highlights the importance of pharmacovigilance in ensuring the safety of medications. It's a reminder that the quest for safer and more effective drugs is a continuous journey, requiring ongoing vigilance, research, and collaboration among healthcare professionals.

Date :
  1. Date Completed 2013-02-19
  2. Date Revised 2015-11-19
Further Info :

Pubmed ID

23367709

DOI: Digital Object Identifier

23367709

Related Literature

Article Analysis
・Side Effects of aliskiren
SNS
PICO Info
in preparation
Languages

French

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.